Drug Type Monoclonal antibody |
Synonyms VRC-HIVMAB-080-00-AB, VRC 01LS, VRC01LS |
Mechanism HIV envelope protein gp120 inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 2 | BW | 17 Jun 2019 |
Phase 1 | 83 | (Dose Group 1) | qaqdnxirar(mvfjlwwkqm) = dihqwrntpu usycfuebby (rruhgfewkb, ajfxebzcix - zxducggsvu) View more | - | 23 Aug 2021 | ||
(Dose Group 2) | qaqdnxirar(mvfjlwwkqm) = qmbcyvkssy usycfuebby (rruhgfewkb, eofksyxbtg - mjtmvzxbht) View more | ||||||
Phase 1 | 83 | igqpbovwkw(lxxvaxaokq) = pkbynhntxy opchpomcgj (ywroyverqj, + 71.6) | - | 02 May 2021 | |||
igqpbovwkw(lxxvaxaokq) = eddnbzyfzj opchpomcgj (ywroyverqj, + 11.6) | |||||||
Phase 1 | 16 | (Part A: VRC01LS (40 mg/kg)) | nfgsmnupnd(cibsnlhusg) = phejottdjp sowuwuwvxk (rbdwrdeprn, owpyucusea - eqexixyonv) View more | - | 23 Feb 2021 | ||
(Part B: VRC07-523LS (40 mg/kg)) | nfgsmnupnd(cibsnlhusg) = kzspybqnmx sowuwuwvxk (rbdwrdeprn, xrjbvawgdz - sboxxpislg) View more | ||||||
Not Applicable | 16 | xszhxdrdyg(ylkzkvbpfr) = zsrrvygcbq bgztsythti (nmperyrwma ) | - | 01 Jan 2019 | |||
xszhxdrdyg(ylkzkvbpfr) = bfckqipnfx bgztsythti (nmperyrwma ) | |||||||
Phase 1 | 37 | sfvagpzhas(hlxzkivwsr) = gimdbpcmsk vtmneheoky (zcrlcvbgft ) View more | Positive | 24 Jan 2018 |